Novartis Launches Flagship U.S. Hub to Secure Drug Manufacturing
EAST HANOVER, N.J. — December 12, 2025 — Novartis, a global innovative medicines company, has officially broken ground on...
patient access
Advertisement
Scemblix® Gets Priority Access Under Ontario’s FAST Program
MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...
Biocon Biologics Expands Insulin Glargine Access in U.S.
BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded...
BioCryst Acquires Astria Therapeutics to Expand HAE Pipeline
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
Kedrion Biopharma Launches YIMMUGO® for PI in the U.S.
FORT LEE, N.J., October 9, 2025 — Kedrion Biopharma today announced the U.S. commercial launch of YIMMUGO® (Immune Globulin...
Advertisements
Kedrion Biopharma Secures FDA Nod for QIVIGY® and Expands U.S. Growth Plan
September 29, 2025 – Kedrion Biopharma announced a major regulatory and strategic milestone with the U.S. Food and Drug...
Solid Biosciences Licenses AAV-SLB101 Capsid to Advance Gene Therapies
CHARLESTOWN, Mass., Sept. 23, 2025 — Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize...
FDA Accelerates First-Ever Barth Syndrome Therapy, FORZINITY™
NEEDHAM, Mass., September 19, 2025 – Stealth BioTherapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA)...
FDA Approves J&J’s INLEXZO™, Redefining Bladder Cancer Care
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....
FDA Grants Breakthrough Therapy Status to Olomorasib for Lung Cancer
INDIANAPOLIS, Sept. 4, 2025 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib,...
Advertisement
